Table 2.
Corroboration of the genetic overlap between PD and the blood levels of 25 lipids displaying significant genetic sharing with PD in phase I.
| Phase I | Phase II | |||||
|---|---|---|---|---|---|---|
| PT | P value | R2 | PT | P value | R2 | |
| 18:4n3 | 0.3 | 1.34E-07 | 3.60E-03 | 0.4 | 4.82E-02 | 3.77E-04 |
| 20:3n3 or n6 | 0.2 | 4.12E-07 | 3.30E-03 | 0.5 | 3.38E-05 | 2.16E-03 |
| 20:4n6 | 0.3 | 4.51E-06 | 2.67E-03 | 0.5 | 1.33E-06 | 2.99E-03 |
| 20:5n3 | 0.3 | 2.19E-09 | 4.66E-03 | 0.5 | 1.17E-03 | 1.26E-03 |
| AC 2:0 | 0.2 | 6.73E-06 | 2.53E-03 | 0.5 | 1.70E-02 | 6.01E-04 |
| AC 8:1 | 0.2 | 1.14E-05 | 2.40E-03 | 0.5 | 1.25E-02 | 6.72E-04 |
| AC 14:2 | 0.4 | 1.61E-15 | 1.07E-02 | 0.1 | 3.20E-03 | 1.29E-03 |
| AC 18:0 | 0.4 | 1.11E-06 | 3.30E-03 | 0.1 | 3.04E-02 | 5.20E-04 |
| MAG 18:1 | 0.4 | 1.08E-09 | 6.57E-03 | 0.1 | 4.78E-04 | 2.01E-03 |
| TAG 44:1 | 0.4 | 2.01E-06 | 1.02E-02 | 0.4 | 1.02E-05 | 1.01E-02 |
| TAG 46:1 | 0.4 | 1.37E-05 | 8.43E-03 | 0.3 | 1.18E-05 | 9.90E-03 |
| TAG 46:2 | 0.4 | 1.62E-06 | 1.04E-02 | 0.3 | 1.03E-05 | 1.00E-02 |
| TAG 48:0 | 0.4 | 1.91E-05 | 8.13E-03 | 0.4 | 1.42E-06 | 1.21E-02 |
| PC aa 32:3 | 0.4 | 1.85E-05 | 2.27E-03 | 0.5 | 1.23E-04 | 1.80E-03 |
| PC ae 32:2 | 0.4 | 1.52E-06 | 2.91E-03 | 0.05 | 2.58E-03 | 1.05E-03 |
| PC ae 38:1 | 0.5 | 5.14E-06 | 2.97E-03 | 0.3 | 2.19E-03 | 1.24E-03 |
| PC ae 44:6 | 0.4 | 8.19E-06 | 2.48E-03 | 0.05 | 2.79E-02 | 4.90E-04 |
| LPC 16:0 | 0.3 | 8.82E-07 | 3.05E-03 | 0.001 | 3.59E-03 | 9.67E-04 |
| LPC 17:0 | 0.5 | 8.52E-11 | 5.44E-03 | 0.3 | 9.83E-04 | 1.28E-03 |
| LPC 18:0 | 0.5 | 1.95E-19 | 1.06E-02 | 0.001 | 3.39E-03 | 9.80E-04 |
| SM 26:0 | 0.5 | 4.21E-27 | 1.73E-02 | 0.3 | 3.00E-05 | 2.45E-03 |
| SM 26:1 | 0.4 | 5.32E-06 | 2.59E-03 | 0.001 | 6.22E-04 | 1.39E-03 |
| CE 20:5 | 0.5 | 8.10E-07 | 1.10E-02 | 0.5 | 1.33E-02 | 2.73E-03 |
| 4-androsten-3beta,17beta-diol disulfate 1 | 0.5 | 3.75E-07 | 3.32E-03 | 0.3 | 1.12E-03 | 1.27E-03 |
| HDL-C | 0.2 | 1.02E-05 | 0.000841378 | 0.05 | 1.09E-01 | 7.01E-05 |
AC acylcarnitine, MAG monoacylglycerol, TAG triacylglycerol, PC phosphatidylcholine, PD Parkinson’s disease, aa diacyl, ae acyl-alkyl, LPC lysophosphatidylcholine, SM sphingomyelin, CE cholesterol ester, HDL high-density lipoprotein.
Comparison of the most significant P value threshold (PT), P value, and explained variance (R2) for the results obtained in phases I and II. Significant results after Bonferroni correction (phase I: P < 1.93E-05; phase II: P < 2.86E-04), are highlighted in bold. In total, eight lipids show significant genetic sharing with PD in both phase I and II.